PremiumThe FlyPaxMedica reports first patient treated with PAX-101 for HAT PaxMedica files Nasdaq delisting appeal notice PaxMedica prepares to file NDA for use of suramin in HAT PremiumCompany AnnouncementsPaxMedica Releases Updated Investor Presentation Online PaxMedica Accelerates RSU Vesting for Top Executives PaxMedica initiated with a Buy at H.C. Wainwright PremiumThe FlyPaxMedica acquires certain suramin research assets from RLS PaxMedica announces 1-for-17 reverse stock split PaxMedica says research on suramin for autism spectrum disorder to be published 
